Journal Update Archive
Click here to return to the current journals.
Section One
This Section is eligible for 60 minutes of CME credit. All articles in the Section must be completed before applying for CME credit.
- Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: The CHARM trial.
Colombel JF, Sandborn WJ, Rutgeerts P, et al. - Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children.
Hyams J, Crandall W, Kugathasan S, REACH Study Group, et al. - Cytomegalovirus is frequently reactivated and disappears without antiviral agents in ulcerative colitis patients.
Matsuoka K, Iwao Y, Mori T, et al. - Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine.
Sparrow MP, Hande SA, Friedman S, et al.
Section Two
This Section is eligible for 4.25 AMA PRA Category 1 Credit(s). Please read all articles in the section before applying for CME credits.
- Predictors of early response to infliximab in patients with ulcerative colitis
Ferrante F, Vermeire S, Katsanos KH, et al. - Differentiating ulcerative colitis from Crohn’s disease in children and young adults: Report of a Working Group of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition and the Crohn’s and Colitis Foundation of America.
Working Group of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition and the Crohn's and Colitis Foundation of America - Predicting a change in diagnosis from ulcerative colitis to Crohn’s disease: A nested, case-control study.
Melmed GY, Elashoff R, Chen GC, et al. - Certolizumab pegol for the treatment of Crohn’s disease.
Sandborn WJ, Feagan BG, Stoinov S, et al, for the PRECISE 1 Study Investigators - Maintenance therapy with certolizumab pegol for Crohn’s disease (PRECISE 2).
Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al, for the PRECISE 2 Study Investigators - Adalimumab induction therapy for Crohn’s disease previously treated with infliximab: A randomized trial (GAIN).
Sandborn WJ, Rutgeerts P, Enns R, et al.
Section Three
This Section is eligible for 1.0 AMA PRA Category 1 Credit(s). Please read all articles in the section before applying for CME credits.
- Mucosal T-cell immunoregulation varies in early and late Crohn's disease
Kugathasan S, Saubermann L, Smith L, et al. - CT enterography for Crohn's disease: Accurate preoperative diagnostic imaging
Vogel J, da Luz Moreira A, Baker M, et al. - Mucosal healing in inflammatory bowel disease: Results for a Norwegian population-based cohort
Frøslie KF, Jahnsen J, Moum BA, et al. - Natalizumab for the treatment of active Crohn's disease: Results of the ENCORE trial
Targan SR, Feagan BG, Fedorak RN, et al.
Section Four
This Section is eligible for 1.75 AMA PRA Category 1 Credit(s). Please read all articles in the section before applying for CME credits.
- NEW: Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease
Vermeire S, Noman M, Van Assche G, et al. - NEW: Crohn's disease patients' risk–benefit preferences: Serious adverse event risks versus treatment efficacy
Johnson FR, Özdemir S, Mansfield C, et al. - NEW: Quantifying exposure to diagnostic medical radiation in patients with
inflammatory bowel disease: Are we contributing to malignancy?
Newnham E, Hawkes E, Surender A, et al. - NEW: Vertebral fractures and role of low bone mineral density in Crohn's disease
Siffledeen JS, Siminoski K, Jen H, Fedorak RN. - NEW: Thiopurine-induced liver injury in patients with inflammatory bowel disease: A systematic review
Gisbert JP, González-Lama Y, Maté J. - NEW: Antibiotics in Crohn's Disease Study Group. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease
Selby W, Pavli P, Crotty B, et al. - NEW: Utility of magnetic resonance imaging in small bowel Crohn’s disease
Martin DR, Lauenstein T, Sitaraman SV.
